利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.025 秒)

    POLYURETHANE FOAM AND RESIN COMPOSITION
    3.
    发明申请
    POLYURETHANE FOAM AND RESIN COMPOSITION 审中-公开
    聚氨酯泡沫和树脂组合物

    公开(公告)号：US20130059934A1

    公开(公告)日：2013-03-07

    申请号：US13604043

    申请日：2012-09-05

    申请人： Kevin Burgess ,  Greg Gardin ,  Chris Janzen

    发明人： Kevin Burgess ,  Greg Gardin ,  Chris Janzen

    IPC分类号： C08G18/32 ,  C09K3/00 ,  C08J9/14

    CPC分类号： C08G18/4829 ,  C08G18/36 ,  C08G18/482 ,  C08G18/5021 ,  C08G18/6696 ,  C08G2101/005 ,  C08J9/146 ,  C08J2203/142 ,  C08J2203/182 ,  C08J2375/04

    摘要： A polyurethane foam and a resin composition that may be used to form the polyurethane foam are provided. The resin composition includes a first polyol based upon ethylene diamine and having about 100% ethylene oxide capping and present in an amount of from about 0.3 to about 15 parts by weight based on 100 parts by weight of the resin composition, a second polyol, and a physical blowing agent having at least 4 carbon atoms. The polyurethane foam includes the reaction product of an isocyanate component and the resin composition comprising the first and second polyol, in the presence of the physical blowing agent. A method of forming the polyurethane foam on a substrate combines the isocyanate component and the resin composition to form a reaction mixture. The reaction mixture is applied onto the substrate to form the polyurethane foam.

    摘要翻译： 提供可用于形成聚氨酯泡沫的聚氨酯泡沫和树脂组合物。 树脂组合物包括基于乙二胺的第一多元醇，并且具有约100％的环氧乙烷封端，并且其量为约0.3至约15重量份，基于100重量份的树脂组合物，第二多元醇和 具有至少4个碳原子的物理发泡剂。 在物理发泡剂的存在下，聚氨酯泡沫包括异氰酸酯组分与包含第一和第二多元醇的树脂组合物的反应产物。 在基材上形成聚氨酯泡沫的方法将异氰酸酯组分和树脂组合物组合以形成反应混合物。 将反应混合物施加到基材上以形成聚氨酯泡沫。

    PLANETARY GEAR BALL VALVE
    4.
    发明申请
    PLANETARY GEAR BALL VALVE 有权
    行星齿轮球阀

    公开(公告)号：US20130026397A1

    公开(公告)日：2013-01-31

    申请号：US13360672

    申请日：2012-01-28

    申请人： Kevin Burgess ,  David Yakos ,  Bryan Walthall

    发明人： Kevin Burgess ,  David Yakos ,  Bryan Walthall

    IPC分类号： F16K31/08

    CPC分类号： F16K5/0621 ,  F16K5/0647 ,  F16K31/535

    摘要： A stemless ball valve comprising a first flange, second flange, ball, inner magnetic cartridge, outer magnetic cartridge, and planetary gear assembly. The inner magnetic cartridge is situated inside of the outer magnetic cartridge, and the inner and outer magnetic cartridges actuate the valve. The planetary gear assembly is situated between the inner magnetic cartridge and the ball. The planetary gear assembly comprises one or more planetary gear phases, each planetary gear phase comprising a step-down gear. Each planetary gear phase comprises one or more planetary gears that engage with the inner teeth of the outer ring of the planetary gear assembly and with a step-down gear. The invention further comprises a pressure equalization system comprising inner and outer equalization tubes, a piston situated between the inner and outer equalization tubes, and either a piston spring or spring washer stack that biases the piston in the direction of the clean oil.

    摘要翻译： 一种无级球阀，包括第一凸缘，第二凸缘，球，内磁盒，外磁盒和行星齿轮组件。 内部磁盘盒位于外部磁性盒的内部，内部和外部磁带驱动阀。 行星齿轮组件位于内部磁盘盒和球之间。 行星齿轮组件包括一个或多个行星齿轮相，每个行星齿轮相包括降档齿轮。 每个行星齿轮相包括与行星齿轮组件的外圈的内齿接合的一个或多个行星齿轮和降档齿轮。 本发明还包括压力均衡系统，其包括内和外平衡管，位于内和外平衡管之间的活塞，以及活塞弹簧或弹簧垫圈叠层，其沿着清洁油的方向偏压活塞。

    ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER
    5.
    发明申请
    ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER 审中-公开

    公开(公告)号：US20110212955A1

    公开(公告)日：2011-09-01

    申请号：US13119904

    申请日：2009-07-02

    申请人： Hong Boon Lee ,  Kevin Burgess ,  Siang Hui Lim ,  Liangxing Wu

    发明人： Hong Boon Lee ,  Kevin Burgess ,  Siang Hui Lim ,  Liangxing Wu

    IPC分类号： A61K31/5377 ,  C07D405/14 ,  A61K31/4025 ,  A61K31/4545 ,  C07D413/14 ,  A61K31/496 ,  C07D405/04 ,  C07D413/04 ,  A61P35/00 ,  A61P35/02

    CPC分类号： A61K31/352 ,  A61K31/4025 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5375 ,  C07D311/82 ,  C07D311/86 ,  C09B11/24 ,  C09B11/26

    摘要： The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R1 represents aryl, Het1 or C1-6 alkyl, which latter group is optionally substituted by aryl or Het2; R2a and R2b together form C3.8 n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O—C1-4, alkyl and which alkylene group is optionally interrupted by X1; R3a and R3b together form C3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo. C1-4 alkyl, C(O)OH and C(O)O—C1-4 alkyl, and which alkylene group is optionally interrupted by X2; X1 and X2 independently represent O, S, or NR4; R4 represents, independently at each occurrence, H, C(O)OR5, C(O)R6a, C(O)N(R6b)R6c or C1-6, alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het3 or is substituted by a single C(O)OR1a group; R4a represents H or C1-4 alkyl; R5 represents aryl, Het4 or C1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het5; R5e to R6d independently represent H or R5; each aryl independently represents a C6-10carbocylic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR7, phenyl, napthyl and Het6) and OR8; R7 and R8 independently represent H, C1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR8a substituent), Het7, phenyl or naphthyl; R8a represents H or C1-4 alkyl; Het1 to Het7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulphur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR9 and phenyl) and OR10; R9 and R10 independently represent H, C1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A′ represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions.

    Stemless ball valve
    8.
    发明授权
    Stemless ball valve 有权
    无阀球阀

    公开(公告)号：US07971855B2

    公开(公告)日：2011-07-05

    申请号：US12331387

    申请日：2008-12-09

    申请人： Kevin Burgess ,  David Yakos ,  Bryan Walthall

    发明人： Kevin Burgess ,  David Yakos ,  Bryan Walthall

    IPC分类号： F16K5/06

    CPC分类号： F16K31/088 ,  F16K5/0621 ,  F16K5/0647 ,  F16K5/20 ,  Y10T137/86871

    摘要： A stemless ball valve comprising two flanges and a ball with a channel, two axis pins and two travel pins. One end of each axis and travel pin is fixedly attached to the ball, and the other end of each axis pin is lodged into a notch in the first or second flange such that the axis pin is allowed to rotate in the notch. The guide sleeve comprises two channels, and one end of each travel pin is situated within one of the two channels in the guide sleeve. An outer magnetic cartridge causes the inner magnetic cartridge and guide sleeve to rotate, and when the guide sleeve rotates, the travel pins move up and down within the channels in the guide sleeve. The movement of the travel pins within the channels in the guide sleeve causes the ball to rotate, thereby opening and closing the ball valve.

    摘要翻译： 一种无杆球阀，包括两个凸缘和一个带通道，两个轴销和两个行程销的球。 每个轴和行程销的一端固定地附接到球，并且每个轴销的另一端被放置在第一或第二凸缘中的凹口中，使得轴销允许在凹口中旋转。 引导套筒包括两个通道，每个行程销的一端位于导向套筒中的两个通道中的一个内。 外部磁盘盒使内部磁盘盒和引导套筒旋转，并且当导向套筒旋转时，行程销在导向套筒的通道内上下移动。 行程销在导向套筒的通道内的运动导致球旋转，从而打开和关闭球阀。

    β-turn peptidomimetic cyclic compounds
    10.
    发明授权
    β-turn peptidomimetic cyclic compounds 有权
    β-转角肽模拟环状化合物

    公开(公告)号：US06881719B2

    公开(公告)日：2005-04-19

    申请号：US10181546

    申请日：2001-01-18

    申请人： Horacio Uri Saragovi ,  Kevin Burgess

    发明人： Horacio Uri Saragovi ,  Kevin Burgess

    IPC分类号： A61K31/00 ,  A61K31/395 ,  A61K38/12 ,  A61K38/06 ,  A61K38/07

    CPC分类号： A61K31/00 ,  A61K31/395 ,  A61K38/12

    摘要： Proteolytically stable small molecule β-turn peptidomimetic compounds have been identified as agonists or antagonists of neurotrophin receptors, such as TrkA. A compound of particular interest binds the immunoglobulin-like C2 region of the extracellular domain of TrkA, competes the binding of another TrkA ligand, affords selective trophic protection to TrkA-expressing cell lines and neuronal primary cultures, and induces the differentiation of primary neuronal cultures. The small β-turn peptidomimetic compounds of the invention can activate a tyrosine kinase neurotrophin receptor that normally binds a relatively large protein ligand. Such compounds that bind the extracellular domain of Trk receptors are useful pharmacological agents to address disorders where Trk receptors play a role, by targeting populations selectively.

    摘要翻译： 蛋白水解稳定的小分子β-转角拟肽化合物已被鉴定为神经营养因子受体的激动剂或拮抗剂，如TrkA。 特别感兴趣的化合物结合TrkA细胞外结构域的免疫球蛋白样C2区域竞争另一个TrkA配体的结合，为表达TrkA的细胞系和神经元原代培养物提供选择性营养保护，并诱导原代神经元培养物的分化 。 本发明的小β-转角拟肽化合物可以激活通常结合相对大的蛋白质配体的酪氨酸激酶神经营养因子受体。 结合Trk受体的细胞外结构域的这些化合物是通过选择性靶向群体来解决Trk受体起作用的病症的有用的药理学试剂。